- Home
- ADIL vs ATNF Comparison
ADIL vs ATNF Comparison
Compare ADIL & ATNF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADIL
- ATNF
- Stock Information
- Founded
- ADIL 2010
- ATNF 2016
- Country
- ADIL United States
- ATNF United States
- Employees
- ADIL N/A
- ATNF N/A
- Industry
- ADIL Biotechnology: Pharmaceutical Preparations
- ATNF Biotechnology: Pharmaceutical Preparations
- Sector
- ADIL Health Care
- ATNF Health Care
- Exchange
- ADIL Nasdaq
- ATNF Nasdaq
- Market Cap
- ADIL 4.3M
- ATNF 4.1M
- IPO Year
- ADIL 2018
- ATNF N/A
- Fundamental
- Price
- ADIL $0.60
- ATNF $0.84
- Analyst Decision
- ADIL Strong Buy
- ATNF
- Analyst Count
- ADIL 1
- ATNF 0
- Target Price
- ADIL $8.00
- ATNF N/A
- AVG Volume (30 Days)
- ADIL 72.0K
- ATNF 41.8K
- Earning Date
- ADIL 05-13-2025
- ATNF 05-14-2025
- Dividend Yield
- ADIL N/A
- ATNF N/A
- EPS Growth
- ADIL N/A
- ATNF N/A
- EPS
- ADIL N/A
- ATNF N/A
- Revenue
- ADIL N/A
- ATNF N/A
- Revenue This Year
- ADIL N/A
- ATNF N/A
- Revenue Next Year
- ADIL N/A
- ATNF N/A
- P/E Ratio
- ADIL N/A
- ATNF N/A
- Revenue Growth
- ADIL N/A
- ATNF N/A
- 52 Week Low
- ADIL $0.61
- ATNF $0.83
- 52 Week High
- ADIL $3.10
- ATNF $17.75
- Technical
- Relative Strength Index (RSI)
- ADIL 36.45
- ATNF 29.28
- Support Level
- ADIL $0.67
- ATNF $0.90
- Resistance Level
- ADIL $0.72
- ATNF $1.02
- Average True Range (ATR)
- ADIL 0.05
- ATNF 0.08
- MACD
- ADIL -0.00
- ATNF -0.01
- Stochastic Oscillator
- ADIL 0.00
- ATNF 11.08
About ADIL Adial Pharmaceuticals Inc
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.
About ATNF 180 Life Sciences Corp.
180 Life Sciences Corp is a clinical-stage biotechnology company. It is focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation and fibrosis by employing innovative research, and, where appropriate, combination therapy.